Capital Advisory Group Advisory Services’s ARK Genomic Revolution ETF ARKG Stock Holding History

Capital Advisory Group Advisory Services’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-570	Closed	-$17K	–	143
2022 Q2	$17K	Sell	570 -100	-15%	-$3.5K	0.01%	176
2022 Q1	$31K	Buy	+670	New	+$31.9K	0.01%	270
2021 Q4	–	Sell	-6,710	Closed	-$501K	–	189
2021 Q3	$501K	Buy	6,710 +6	+0.1%	+$503	0.18%	119
2021 Q2	$620K	Sell	6,704 -171	-2%	-$14.5K	0.23%	97
2021 Q1	$610K	Buy	+6,875	New	+$682K	0.24%	99

Other funds holding ARKG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Capital Advisory Group Advisory Services's ARKG Position: Q3 2022 in Review

Capital Advisory Group Advisory Services sold out of ARK Genomic Revolution ETF (ARKG) in Q3 2022, closing a stake of 570 shares — an estimated $17K sold.

Capital Advisory Group Advisory Services first reported a position in ARKG in Q1 2021 and held it in 5 quarters. The position peaked at $620K in Q2 2021. 311 funds tracked by Wall St. Rank hold ARKG as of Q3 2022.

Capital Advisory Group Advisory Services reported no remaining ARK Genomic Revolution ETF position as of Q3 2022 after selling out during the quarter.
Capital Advisory Group Advisory Services sold 570 ARK Genomic Revolution ETF shares in Q3 2022, an estimated $17K.
Capital Advisory Group Advisory Services first reported a position in ARK Genomic Revolution ETF in Q1 2021 and held it in 5 quarters.
Capital Advisory Group Advisory Services's ARK Genomic Revolution ETF position peaked at $620K in Q2 2021.
311 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q3 2022.

Based on Capital Advisory Group Advisory Services's 13F filing for Q3 2022, filed 7 Nov 2022.